Oxford Asset Management’s Harvard Bioscience HBIO Stock Holding History

Oxford Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$281K	Sell	12,718 -13,415	-51%	-$363K	0.04%	96
2019 Q4	$797K	Sell	26,133 -4,802	-16%	-$138K	0.02%	996
2019 Q3	$951K	Buy	30,935 +9,558	+45%	+$238K	0.02%	972
2019 Q2	$428K	Buy	21,377 +8,931	+72%	+$262K	0.01%	1331
2019 Q1	$536K	Sell	12,446 -4,863	-28%	-$176K	0.01%	1190
2018 Q4	$550K	Sell	17,309 -3,694	-18%	-$146K	0.01%	1156
2018 Q3	$1.09M	Buy	21,003 +4,493	+27%	+$252K	0.02%	965
2018 Q2	$876K	Buy	16,510 +10,819	+190%	+$554K	0.02%	1108
2018 Q1	$285K	Buy	+5,691	New	+$255K	0.01%	1415
2016 Q3	–	Sell	-1,239	Closed	-$35K	–	804
2016 Q2	$35K	Buy	+1,239	New	+$39.4K	﹤0.01%	765

Other funds holding HBIO

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Oxford Asset Management's HBIO Position: Q1 2020 in Review

Oxford Asset Management reduced its Harvard Bioscience (HBIO) stake by 51% in Q1 2020, selling an estimated $363K and leaving 12,718 shares worth $281K. The position accounts for 0.04% of the portfolio, ranked #96.

Oxford Asset Management first reported a position in HBIO in Q2 2016 and has held it in 10 quarters since. The position peaked at $1.09M in Q3 2018. 64 funds tracked by Wall St. Rank hold HBIO as of Q1 2020.

Oxford Asset Management held 12,718 shares of Harvard Bioscience worth $281K as of Q1 2020.
Oxford Asset Management sold 13,415 Harvard Bioscience shares in Q1 2020, an estimated $363K.
Harvard Bioscience made up 0.04% of Oxford Asset Management's portfolio in Q1 2020, its #96 holding.
Oxford Asset Management first reported a position in Harvard Bioscience in Q2 2016 and has held it in 10 quarters since.
Oxford Asset Management's Harvard Bioscience position peaked at $1.09M in Q3 2018.
64 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.